Elevated creatine phosphokinase and rhabdomyolysis associated with elexacaftor/tezacaftor/ivacaftor use in cystic fibrosis

Pediatr Pulmonol. 2024 Jun;59(6):1795-1797. doi: 10.1002/ppul.26980. Epub 2024 Mar 22.

Authors

Cameron J McKinzie¹, Charissa W Kam¹, Morgan C Jones¹, Laura B Gifford², Ceila E Loughlin³, Terry L Noah³, Vivek K Shenoy⁴, Elisabeth P Dellon³

Affiliations

¹ Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA.
² Division of Pulmonary Diseases & Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
³ Division of Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
⁴ Division of Gastroenterology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.

PMID: 38517044
DOI: 10.1002/ppul.26980

No abstract available

Keywords: creatine phosphokinase; cystic fibrosis; elexacaftor/tezacaftor/ivacaftor.

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Aminophenols* / adverse effects
Aminophenols* / therapeutic use
Benzodioxoles* / adverse effects
Benzodioxoles* / therapeutic use
Creatine Kinase* / blood
Cystic Fibrosis* / complications
Cystic Fibrosis* / drug therapy
Drug Combinations*
Humans
Indoles* / adverse effects
Pyrazoles* / adverse effects
Pyridines / adverse effects
Pyridines / therapeutic use
Pyrroles / adverse effects
Pyrrolidines
Quinolines / adverse effects
Quinolines / therapeutic use
Quinolones / adverse effects
Quinolones / therapeutic use
Rhabdomyolysis* / chemically induced
Thiophenes / adverse effects
Thiophenes / therapeutic use

Substances

Aminophenols
Benzodioxoles
Creatine Kinase
Drug Combinations
elexacaftor
elexacaftor, ivacaftor, tezacaftor drug combination
Indoles
Pyrazoles
Pyridines
Pyrroles
Pyrrolidines
Quinolines
Quinolones
Thiophenes